TABLE 1.
Summary of Patient Phenotypes
| UNC Non-IBD Patients (n = 23) | UNC CD Patients (n = 46) | WashU CD Patients (n = 79) | ||||
|---|---|---|---|---|---|---|
| Non-IBD Colon (n = 16) | Non-IBD Ileum (n = 9) | CD Colon (n = 21) | CD Ileum (n = 33) | CD Ileum (n = 79) | ||
| Pathology | Noninflamed | 16 | 9 | 15 | 25 | 79 |
| Inflamed | 0 | 0 | 9 | 24 | 0 | |
| Matched | 0 | 0 | 3 | 16 | 0 | |
| Race | Caucasian | 12 | 9 | 11 | 20 | 73 |
| African American | 4 | 0 | 4 | 4 | 5 | |
| Other | 0 | 0 | 0 | 1 | 1 | |
| Ethnicity | Not Hispanic | 13 | 8 | 9 | 16 | 18 |
| Hispanic | 1 | 1 | 2 | 0 | 1 | |
| Not reported | 2 | 0 | 4 | 9 | 60 | |
| Sex | Female | 11 | 7 | 13 | 13 | 48 |
| Male | 5 | 2 | 2 | 12 | 31 | |
| Agea, y | 56.7 (15.0) | 59.1 (19.0) | 34.6 (12.8) | 37.3 (14.7) | 38.0 (13.5) | |
| Disease behavior | Inflammation (B1) | N/A | N/A | 6 | 0 | 4 |
| Stricturing (B2) | N/A | N/A | 6 | 16 | 42 | |
| Penetrating (B3) | N/A | N/A | 3 | 9 | 33 | |
| Disease location | Colon-only (L1) | N/A | N/A | 1 | 4 | 39 |
| Ileum-only (L2) | N/A | N/A | 4 | 0 | 0 | |
| Colon and ileum (L3) | N/A | N/A | 10 | 21 | 40 | |
| Smoking status | Never | 9 | 5 | 8 | 12 | 36 |
| Current smoker | 3 | 1 | 3 | 5 | 17 | |
| Former smoker | 4 | 3 | 4 | 8 | 25 | |
| Recurrence | Unknown | 16 | 9 | 6 | 5 | 15 |
| No recurrence | N/A | N/A | 6 | 11 | 43 | |
| Recurrence | N/A | N/A | 3 | 9 | 21 | |
| 5-ASAs | No current use | 9 | 16 | 13 | 19 | 54 |
| Current use | N/A | N/A | 2 | 6 | 25 | |
| Immunomodulators | No current use | 9 | 16 | 8 | 16 | 46 |
| Current use | N/A | N/A | 7 | 9 | 33 | |
| Steroids | No current use | 15 | 8 | 5 | 17 | 50 |
| Current use | 1 | 1 | 10 | 8 | 29 | |
| anti-TNFs | No current use | 16 | 9 | 5 | 13 | 42 |
| Current use | N/A | N/A | 10 | 12 | 37 | |
aThe values in parenthesis are standard deviations.
5-ASAs indicate 5-aminosalicylates. B1, inflammation; B2, stricturing; B3, penetrating; L1, colon-only; L2, ileum-only; L3, colon and ileum.